Novel concepts of statin therapy for cardiovascular risk reduction in hypertension

Current Pharmaceutical Design

Volumn 12, Issue 13, 2006, Pages 1593-1609

  Varughese, George I ^a   Patel, Jeetesh V ^a   Lip, Gregory Y H ^a   Varma, Chetan ^a  

^a SANDWELL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Dyslipidemia; Endothelial dysfunction; HMG CoA reductase; Hypercholesterolemia; Lipoprotein; Platelets; Pleiotropic effect

Indexed keywords

ATORVASTATIN; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CERIVASTATIN; CHOLESTEROL ESTER; CLOPIDOGREL; CYTOCHROME P450; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PADGEM PROTEIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID ANALYSIS; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INFLAMMATION; LIPID METABOLISM; RISK FACTORS; TUNICA INTIMA;

EID: 33646524750     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776843304     Document Type: Review

References (138)

1. Michaud CM, Murray CJ, Bloom BR. Burden of diseaseimplications for future research. JAMA 2001; 285(5): 535-539.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104:2746-2753.
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-2864.
4. Nadar S, Lim HS, Beevers DG, Lip GY. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16(12): 815-817.
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-952.
6. Pedrinelli R, Esposti ED, Dell'Omo G. LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis 2005; 180(1): 137-143.
7. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care. JAMA 2002; 288: 2998-3007.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
10. Prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301-1307.
12. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
13. Athyros VG, Papageorgiou AA, Mercouris BR. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Curr Med Res Opin 2002; 18: 220-228.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
15. The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
16. The Long-Term Intervention with Pravastatin Group in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
17. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolis M, et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomised controlled trial. JAMA 2002; 287: 3215-3222.
18. Lee AJ. Haemorheological, platelet and endothelial factors in essential hypertension. J Hum Hypertens 2002; 16(8): 529-530.
19. Durrington PN. Lipoproteins and their metabolism. In: 'Hyperlipidaemia, diagnosis and management'. Ed 2 Wright publishers. 1989; Chap 2: 23-56.
20. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173(1): 1-12.
21. Libby P. Managing the risk of atherosclerosis: the role of highdensity lipoprotein. Am J Cardiol 2001; 88(12A): 3N-8N.
22. Koeller J, Talbert RL. Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk. Pharmacotherapy 2002; 22(10): 1266-1277.
23. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolaemia. Ann Pharmacother 2002; 36(1): 93-101.
24. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19(1): 117-125.
25. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005; 8(2): 95-97.
26. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38(6): 978-981.
27. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99(1): 95-112.
28. Hughes AD. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. J Hum Hypertens 1996; 10(6): 387-390.
29. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2(3): 208-217.
30. Lip GY. Hypertension, Platelets, and the Endothelium: The "Thrombotic Paradox" of Hypertension (or "Birmingham Paradox") Revisited. Hypertension 2003; 41: 199-200.
31. Virchow R: Phlogose und Thrombose in Geraßsystem. In: Virchow R, ed. Gesammelte Abhandlungen zur Wissenchaftichen Medicin. Frankfurt, Germany: Von Meidinger Sohn; 1856: 458-636.
32. Blann AD, Lip GY, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens 1997; 11: 607-9.
33. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002; 40: 61-66.
34. Quan Sang KH, Devynck MA. Increased platelet cytosolic free calcium concentration in essential hypertension. J Hypertens 1986; 4: 567-574.
35. Gleerup G, Winther K: Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism. Am J Hypertens 1991; 4(2 Pt 2): 168S-171S.
36. Nadar SK, Caine GJ, Blann AD, Lip GY. Platelet adhesion in hypertension: application of a novel assay of platelet adhesion. Ann Med 2005; 37(1): 55-60.
37. Tan KT, Watson SP, Lip GY. The endothelium and platelets in cardiovascular disease: potential targets for therapeutic intervention. Curr Med Chem Cardiovasc Hematol Agents 2004; 2(2): 169-178.
38. Stepien JM, Prideaux RM, Willoughby SR, Chirkov YY, Horowitz JD. Pilot study examining the effect of cholesterol lowering on platelet nitric oxide responsiveness and arterial stiffness in subjects with isolated mild hypercholesterolaemia. Clin Exp Pharmacol Physiol 2003; 30(7): 507-512.
39. Relou IA, Hackeng CM, Akkerman JW, Malle E. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 2003; 60(5): 961-971.
40. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Leo A, et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90(3): 476-482.
41. Ferroni P, Martini F, Cardarello CM, Gazzaniga PP, Davi G, Basili S. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 2003; 108(14): 1673-1675.
42. Tailor A, Lefer DJ, Granger DN. HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2004; 286(4): H1402-407.
43. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 2004; 38(9): 1500-1508.
44. Tekten T, Ceyhan C, Ercan E, Onbasili AO, Turkoglu C. The effect of atorvastatin on platelet function in patients with coronary artery disease. Acta Cardiol 2004; 59(3): 311-315.
45. Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF. Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia. Am J Cardiol 2004; 94(3): 364-366.
46. Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol 2003; 1(2): 157-169.
47. Spieker LE, Noll G, Ruschitzka FT, Maier W, Luscher TF. Working under pressure: the vascular endothelium in arterial hypertension. J Hum Hypertens 2000; 14(10-11): 617-630.
48. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 2004; 10(29): 3591-3605.
49. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349(9055): 837-842.
50. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995; 25: 201-206.
51. Wierzbicki AS, Chowienczyk PJ, Cockcroft JR, Brett SE, Watts GF, Jenkins BS, et al. Cardiovascular risk factors and endothelial dysfunction. Clin Sci (Lond) 2004; 107(6): 609-615.
52. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540-556.
53. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170(2): 315-323.
54. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106(10): 1211-1218.
55. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004; 89(2): 740-747.
56. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40(12): 2117-2121.
57. Heinke S, Schwarz G, Figulla HR, Heinemann SH. The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells. BMC Cardiovasc Disord 2004; 4(1): 4.
58. Ma L, Morita I, Murota S. Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 1994; 203(2): 1355-1361.
59. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19(2): 103-109.
60. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002; 16(10): 705-710.
61. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23(5): 729-736.
62. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62(4): 499-506.
63. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109(21S1): II2-10.
64. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005; 3(1): 63-68.
65. Yu H, Rifai N. High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem 2000; 33(8): 601-610.
66. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE ITTIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352(1): 20-28.
67. Boos CJ, Lip GY. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J Hum Hypertens 2005; 19(7): 511-513.
68. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol 2002; 23(3): 263-277.
69. Zebrack JS, Anderson JL. Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice. Prog Cardiovasc Nurs 2002; 17(4): 174-185.
70. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Maesano A, Schepis F, et al. Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects. Atherosclerosis 2001; 155(1): 143-147.
71. Olsson AG, Schwartz GG, Jonasson L, Linderfalk C. Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol Scand 2002; 176(2): 147-150.
72. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25(9): 742-748.
73. Abbruzzese TA, Havens J, Belkin M, Donaldson MC, Whittemore AD, Liao JK, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39(6): 1178-1185.
74. Mukherjee D, Lingam P, Chetcuti S, Grossman PM, Moscucci M, Luciano AE, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation 2002; 106(15): 1909-1912.
75. Laws PE, Spark JI, Cowled PA, Fitridge RA. The role of statins in vascular disease. Eur J Vasc Endovasc Surg 2004; 27(1): 6-16.
76. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19(2): 149-154.
77. Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K, et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002; 16(2): 121-126.
78. Rice JB, Stoll LL, Li WG, Denning GM, Weydert J, Charipar E, et al. Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol 2003; 23(9): 1576-1582.
79. Vamvakopoulos JE, Green C. HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statinmediated vasculoprotection. BMC Cardiovasc Disord 2003; 3(1): 6.
80. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341(2): 70-76.
81. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
82. Keaney JF, Vita JA. The value of inflammation for predicting unstable angina. N Engl J Med 2002; 347: 55-57.
83. Ridker PM, Rifia N, Pfeffer MD, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Longterm effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-235.
84. Albert MA, Danielson E, Rifai N, Ridker PM, for the Pravastatin Inflammation/CRP Evaluation (PRINCE) Investigators. JAMA 2001; 286: 64-70.
85. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
86. Eto M, Luscher TF. Modulation of coagulation and fibrinolytic pathways by statins. Endothelium 2003; 10(1): 35-41.
87. Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T, et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998; 31(1 Pt 2): 321-327.
88. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783-788.
89. Aigbe A, Famodu AA. Haemorheological and fibrinolytic activity in hypertensive Nigerians. Clin Hemorheol Microcirc 1999; 21: 415-420.
90. Eliasson M, Jansson J, Nilsson P, Asplund K. Enhanced levels of t-PA Ag in essential hypertension. A popular based study in Sweden. J Hypertens 1997; 15: 349-356.
91. Wall U, jem C, Bergbrant A, Jem S. Enhanced levels of tPA-Ag in borderline hypertension. Hypertension 1995; 26: 796-800.
92. Orem C, Uydu HA, Yilmaz R, Gokce M, Baykan M, Eminagaoglu S, et al. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J 2004; 45(6): 977-987.
93. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-269.
94. Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, et al. Cross linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-86.
95. Lip GYH, Blann AD, Jones AF, Lip PL, Beevers DG, et al. Relationship of endothelium, thrombogenesis, and haemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566-1571.
96. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64(4): 196-201.
97. Wada H, Mori Y, Kaneko T, Wakita Y, Minamikawa K, Ohiwa M, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14(6): 829-834.
98. Puccetti L, Bruni F, Bova G, Cercignani M, Pompella G, Auteri A, et al. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. Int J Clin Lab Res 2000; 30(3): 147-156.
99. Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, et al. Platelet-dependent thrombin generation in patients with hyperlipidemia J Am Coll Cardiol 1997; 30(1): 91-96.
100. Puccetti L, Bruni F, Di Renzo M, Bova G, Cercignani M, Iadanza A, et al. Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin. Eur Rev Med Pharmacol Sci 1999; 3(5): 197-204.
101. Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000; 149(1): 111-116.
102. Ambrosi P, Aillaud MF, Habib G, Kreitmann B, Metras D, Luccioni R, et al. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost 2000; 83(1): 46-48.
103. Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79(1): 84-87.
104. Seljeflot I, Tonstad S, Hjermann I, Arnesen H.Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002; 105(4): 285-290.
105. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83(7): 683-690.
106. Bruni F, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Cercigani M, et al. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol 2004; 95(2-3): 269-274.
107. Lorena M, Perolini S, Casazza F, Milani M, Cimminiello C. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb Res 1997; 87(4): 397-403.
108. Holschermann H, Hilgendorff A, Kemkes-Matthes B, Schonburg M, Bauer EP, Tillmanns H, et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000; 69(9): 1830-1836.
109. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103(18): 2248-2253.
110. Szczeklik A, Undas A, Musial J, Gajewski P, Swadzba J, Jankowski M. Antithrombotic actions of statins. Med Sci Monit 2001; 7(6): 1381-1385.
111. Lin TH, Huang CH, Voon WC, Yen HW, Lai HM, Liang HY, et al. The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia. Kaohsiung J Med Sci 2000; 16(12): 600-606.
112. Morishita E, Minami S, Ishino C, Kanno M, Uotani C, Asakura H, et al. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. J Atheroscler Thromb 2002; 9(1): 72-77.
113. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002; 9(4): 178-183.
114. Tartiere JM, Kesri L, Safar H, Girerd X, Bots M, Safar ME, et al. Association between pulse pressure, carotid intima-media thickness and carotid and/or iliofemoral plaque in hypertensive patients. J Hum Hypertens 2004; 18(5): 325-331.
115. Zanchetti A, Crepaldi G, Bond MG, Gallus GV, Veglia F, Ventura A, et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens 2001; 19(1): 79-88.
116. Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis 1995; 117(2): 225-236.
117. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003; 163(15): 1837-1841.
118. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124(6): 548-556.
119. Prati F, Morocutti G, Bernardi G, Sommariva L, Tomai F, Pagano A, et al. The extent of late in-stent neointima formation is modified by treatment with pravastatin: a preliminary study with intravascular ultrasound. Ital Heart J 2002; 3(8): 455-461.
120. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035-2038.
121. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
122. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (TIMI-22) Investigators. N Engl J Med 2004; 350(15): 1495-1504.
123. Isaacsohn JL, LaSalle J, Chao G, Gonasun L. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. Clin Ther 2003; 25(3): 904-918.
124. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-1435.
125. Crook D, Bruce R, Worthington M, Mulcahy D, Patterson D, Wynn V. Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia. Cardiovasc Drugs Ther 1992; 6(6): 633-9.
126. Tomlinson B, Mak TW, Tsui JY, Woo J, Shek CC, Critchley JA, et al. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia. Am J Cardiol 1995; 76(2): 136A-139A.
127. Scandinavian Simvastation Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345(8960): 1274-1275.
128. Devroey D, Velkeniers B, Duquet W, Betz W. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta Cardiol 2003; 58(3): 179-184.
129. Duvall WL, Blazing MA, Saxena S, Guyton JR. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. J Cardiovasc Risk 2002; 9(6): 339-347.
130. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol 1993; 33(6): 574-580.
131. Lijnen P, Celis H, Desager JP, Fagard R. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin. J Hum Hypertens 1995; 9(7): 557-564.
132. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89(8): 893-896.
133. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
134. ASCOT Investigators. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004; 110: III-402. Abstract 1905.
135. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD Statin Study. Circulation 2004; 110: III-402. Abstract 1904.
136. Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des 2004; 10(29): 3615-20.
137. Napoli C, Sica V. Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the riskbenefit profile. Curr Pharm Des 2004; 10(4): 425-32.
138. Walter DH. Insights into early and rapid effects of statin therapy after coronary interventions. Curr Pharm Des 2004; 10(4): 369-73.